HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Imaging the norepinephrine transporter in neuroblastoma: a comparison of [18F]-MFBG and 123I-MIBG.

AbstractPURPOSE:
The norepinephrine transporter (NET) is a critical regulator of catecholamine uptake in normal physiology and is expressed in neuroendocrine tumors like neuroblastoma. Although the norepinephrine analog, meta-iodobenzylguanidine (MIBG), is an established substrate for NET, (123)I/(131)I-MIBG has several clinical limitations for diagnostic imaging. In the current studies, we evaluated meta-[(18)F]-fluorobenzylguanidine ([(18)F]-MFBG) and compared it with (123)I-MIBG for imaging NET-expressing neuroblastomas.
EXPERIMENTAL DESIGN:
NET expression levels in neuroblastoma cell lines were determined by Western blot and (123)I-MIBG uptake assays. Five neuroblastoma cell lines and two xenografts (SK-N-BE(2)C and LAN1) expressing different levels of NET were used for comparative in vitro and in vivo uptake studies.
RESULTS:
The uptake of [(18)F]-MFBG in cells was specific and proportional to the expression level of NET. Although [(18)F]-MFBG had a 3-fold lower affinity for NET and an approximately 2-fold lower cell uptake in vitro compared with that of (123)I-MIBG, the in vivo imaging and tissue radioactivity concentration measurements demonstrated higher [(18)F]-MFBG xenograft uptake and tumor-to-normal organ ratios at 1 and 4 hours after injection. A comparison of 4 hours [(18)F]-MFBG PET (positron emission tomography) imaging with 24 hours (123)I-MIBG SPECT (single-photon emission computed tomography) imaging showed an approximately 3-fold higher tumor uptake of [(18)F]-MFBG, but slightly lower tumor-to-background ratios in mice.
CONCLUSIONS:
[(18)F]-MFBG is a promising radiopharmaceutical for specifically imaging NET-expressing neuroblastomas, with fast pharmacokinetics and whole-body clearance. [(18)F]-MFBG PET imaging shows higher sensitivity, better detection of small lesions with low NET expression, allows same day scintigraphy with a shorter image acquisition time, and has the potential for lower patient radiation exposure compared with (131)I/(123)I-MIBG.
AuthorsHanwen Zhang, Ruimin Huang, Nai-Kong V Cheung, Hongfen Guo, Pat B Zanzonico, Howard T Thaler, Jason S Lewis, Ronald G Blasberg
JournalClinical cancer research : an official journal of the American Association for Cancer Research (Clin Cancer Res) Vol. 20 Issue 8 Pg. 2182-91 (Apr 15 2014) ISSN: 1078-0432 [Print] United States
PMID24573553 (Publication Type: Comparative Study, Journal Article, Research Support, N.I.H., Extramural, Research Support, U.S. Gov't, Non-P.H.S.)
Copyright©2014 AACR.
Chemical References
  • 3-fluorobenzylguanidine
  • Fluorobenzenes
  • Guanidines
  • Norepinephrine Plasma Membrane Transport Proteins
  • Radiopharmaceuticals
  • SLC6A2 protein, human
  • 3-Iodobenzylguanidine
Topics
  • 3-Iodobenzylguanidine (pharmacokinetics)
  • Animals
  • Cell Line, Tumor
  • Diagnostic Imaging (methods)
  • Fluorobenzenes (pharmacokinetics)
  • Guanidines (pharmacokinetics)
  • Humans
  • Immunoblotting
  • Immunohistochemistry
  • Mice
  • Neuroblastoma (metabolism, pathology, radionuclide imaging)
  • Norepinephrine Plasma Membrane Transport Proteins (metabolism)
  • Positron-Emission Tomography (methods)
  • Radiopharmaceuticals (pharmacokinetics)
  • Reproducibility of Results
  • Tissue Distribution
  • Tomography, Emission-Computed, Single-Photon (methods)
  • Transplantation, Heterologous

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: